Vials containing the Pfizer/BioNtech vaccine against the coronavirus disease (COVID-19) are displayed before being used at a mobile vaccine clinic, in Valparaiso, Chile, January 3, 2022.

Rodrigo Garrido | Reuters

Pfizer on Tuesday issued sales guidance of $67 billion to $71 billion for 2023, a decline from its record-breaking 2022 results.

The pharmaceutical company booked $100.3 billion for full-year 2022, an all-time high driven by more than $50 billion in Covid vaccine and antiviral sales.

Pfizer expects revenue for 2023 to decline up to 33% compared with 2022 as the pandemic eases and demand for its Covid portfolio slides. The company expects $13.5 billion in Covid vaccine sales in 2023 and $8 billion in revenue for Paxlovid.

Pfizer is forecasting 2023 earnings of $3.25 to $3.45 per share, as much as a 50% drop from its record $6.58 in 2022. The company booked net income $31.4 billion in 2022, a 43% increase over 2021.

Pfizer’s stock fell 3% in premarket trading.

The drugmaker’s results for the fourth quarter largely met analyst expectations. The company booked net income of nearly $5 billion for the quarter, a 47% increase over the same period in 2021. It generated $24.3 billion in revenue for the quarter.

Here’s how the company performed compared with what Wall Street expected for the fourth quarter, based on analysts’ average estimates compiled by Refinitiv:

  • Adjusted EPS: $1.14 vs. $1.05 expected
  • Revenues: $24.3 billion vs. $24.28 billion

CNBC Health & Science

Read CNBC’s latest global health coverage:

Post source: cnbc

You May Also Like

Crypto bank Signature slides amid Silicon Valley Bank, Silvergate woes

The New York Stock Exchange stands in lower Manhattan after global stocks…

Organized crime is plaguing retailers, spurring debate

America’s biggest retailers say organized retail crime has grown into a multibillion-dollar…

Starbucks olive oil coffee debuts in U.S. this week

Starbucks initial Oleato launch will launch three olive oil-infused drinks in stores…